Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CLD-101
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Calidi Biotherapeutics Receives FDA Clearance for CLD-101 in High-Grade Glioma
Details : CLD-101 is a novel stem-cell based platform designed to deliver oncolytic viruses to tumors. It is beinf evaluated for the treatment of newly diagnosed high grade glioma.
Brand Name : CLD-101
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
September 30, 2024
Lead Product(s) : CLD-101
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : CLD-400
Therapeutic Area : Oncology
Study Phase : Discovery
Sponsor : SIGA Technologies
Deal Size : Undisclosed
Deal Type : Collaboration
Calidi Collaborates with SIGA to Advance RTNova Virotherapy for Lung Cancer
Details : The collaboration aims to support the development of Calidi’s systemic and targeted RTNova (CLD-400) virotherapy platform, which has the potential to provide a universal treatment for all tumor types.
Brand Name : CLD-400
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
June 10, 2024
Lead Product(s) : CLD-400
Therapeutic Area : Oncology
Highest Development Status : Discovery
Sponsor : SIGA Technologies
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : CLD-101
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Ladenburg Thalmann
Deal Size : $2.1 million
Deal Type : Public Offering
Calidi Biotherapeutics Announces Exercise of Warrants for $2.1 Million Gross Proceeds
Details : The company intends to use the net proceeds from this offering to advance the clinical development of NeuroNova (CLD-101) for treating high-grade glioma.
Brand Name : CLD-101
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
May 31, 2024
Lead Product(s) : CLD-101
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Ladenburg Thalmann
Deal Size : $2.1 million
Deal Type : Public Offering
Lead Product(s) : CLD-101
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Ladenburg Thalmann
Deal Size : $6.1 million
Deal Type : Public Offering
Calidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public Offering
Details : The net proceeds will be used for the advancement of company's CLD-101 designed to protect and better distribute the anti-cancer virus to sites of tumors distant from the main tumor mass.
Brand Name : CLD-101
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
April 19, 2024
Lead Product(s) : CLD-101
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Ladenburg Thalmann
Deal Size : $6.1 million
Deal Type : Public Offering
Lead Product(s) : NSC.CRAd-S-pk7
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : City of Hope
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CLD-101 platform, which includes NSC.CRAd-S-pk7, is an allogeneic, “off-the-shelf” therapy comprised of an immortalized NSC line loaded with an engineered oncolytic adenovirus.
Brand Name : CLD-101
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
July 18, 2023
Lead Product(s) : NSC.CRAd-S-pk7
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : City of Hope
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The financing will enable Calidi to continue the advancement of its pipeline including CLD-101, CLD-201, and CLD-202, which utilize a potent allogeneic stem cell and oncolytic virus combination for use in multiple oncology indications.
Brand Name : CLD-101
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
June 23, 2023
Lead Product(s) : AD-MSC-based Oncolytic Virus
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : CIRM
Deal Size : $3.1 million
Deal Type : Funding
Details : SNV1 is composed of allogeneic, adipose-derived mesenchymal stem cells (AD-MSC Based Oncolytic Virus) loaded with the oncolytic vaccinia virus Cal1, targeting a variety of solid tumors including metastatic melanoma, triple negative breast cancer, and adv...
Brand Name : SNV1
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
December 14, 2022
Lead Product(s) : AD-MSC-based Oncolytic Virus
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : CIRM
Deal Size : $3.1 million
Deal Type : Funding
Lead Product(s) : AD-MSC Based Oncolytic Virus
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : SNV1 (AD-MSC based oncolytic virus) is an AD-MSC-delivering CAL1 oncolytic virus used for the treatment of solid tumors (metastatic breast, melanoma, head and neck).
Brand Name : SNV1
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
October 12, 2022
Lead Product(s) : AD-MSC Based Oncolytic Virus
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : AD-MSC Based Oncolytic Virus
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The SNV platform is composed of allogeneic, adipose-derived mesenchymal stem cells (AD-MSC) loaded with an oncolytic agent, such as the vaccinia virus SNV1, and is anticipated to be used in combination with various immunotherapy agents, including blockin...
Brand Name : SNV1
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
May 24, 2022
Lead Product(s) : AD-MSC Based Oncolytic Virus
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : CRAd-pk-S-7,Allogeneic Neural Stem Cell
Therapeutic Area : Oncology
Study Phase : IND Enabling
Recipient : City of Hope
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The agreement grants to Calidi commercial exclusivity in using neural stem cells with the adenovirus known as CRAd-pk-S-7 for oncolytic virotherapy.
Brand Name : CRAd-pk-S-7
Molecule Type : Large molecule
Upfront Cash : Undisclosed
August 16, 2021
Lead Product(s) : CRAd-pk-S-7,Allogeneic Neural Stem Cell
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Recipient : City of Hope
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?